Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA considers meeting on Mifeprex

Executive Summary

Agency is discussing holding a workshop on Clostridium sordellii after determining that four women who died from sepsis following use of Danco's abortifacient Mifeprex (mifepristone) tested positive for the bacteria. FDA notes that tests of lots of mifepristone (also known as RU-486) and misoprostol (which is used in conjunction with Mifeprex) were negative for contamination. Agency issued a public health advisory July 19 concerning the sepsis deaths (1"The Pink Sheet" July 25, 2005, p. 4)...

Agency is discussing holding a workshop on Clostridium sordellii after determining that four women who died from sepsis following use of Danco's abortifacient Mifeprex (mifepristone) tested positive for the bacteria. FDA notes that tests of lots of mifepristone (also known as RU-486) and misoprostol (which is used in conjunction with Mifeprex) were negative for contamination. Agency issued a public health advisory July 19 concerning the sepsis deaths (1 (Also see "Crawford’s First Business After Confirmation: Brief Senators On Mifeprex" - Pink Sheet, 25 Jul, 2005.), p. 4)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel